FYI Resources now trading in the US

|

Published 05-MAY-2021 11:23 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

FYI Resources (ASX:FYI) has begun trading on the US-based OTC market.

FYI commenced trading on the OTC on 4 May, 2021 in the US under the stock code OTCQB: FYIRF.

FYI’s is positioning itself to be a significant producer of 4N (99.99%) and 5N (99.999%) high quality, high purity alumina (HPA) through low carbon and environmental footprint production and adhering to high ESG standards.

Its 100% owned Cadoux Kaolin Project is located 220 kilometres north-east of Perth.

The move to the OTC and a dual listing comes just a month after the company updated its Definitive Feasibility Study (DFS) announcing that the project’s Net Present Value (NPV) has almost doubled from $543M to now over US$1BN.

FYI is now looking to build its North American shareholder base in response to increased US investor interest in its fully integrated and innovative flowsheet design which delivers high quality, high purity alumina (HPA) coupled with excellent project financial metrics (as seen above), a positive ESG impact and increasing investment exposure into electric vehicle and strategic battery minerals supply chain opportunities.

The EV sector is a major market stream for HPA producers. Its application in lithium-ion batteries for the burgeoning electric vehicle and static energy storage markets is growing significantly as it is used as a separator material between the anode and cathode in batteries to increase power, functionality and safety of the battery cells.

HPA is also used in “traditional” markets such as LEDs and other sapphire glass products, substrates, electronics and specialty abrasives.

The US market (as is the Australian market) would also be looking closely at FYI’s Memorandum of Understanding with Alcoa of Australia Ltd. The companies are looking to formalise a joint venture on the development of FYI’s HPA project.

This could be the precursor to an offtake agreement, with a very real prospect of offtake agreements being forged with other global HPA users.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X